Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study.

Mohammad Tasavon GholamhoseiniHeidar SharafiHelena Hl BorbaSeyed Moayed AlavianAsma SabermahaniBehzad Hajarizadeh

Published in: BMJ open (2022)

Initiating all patients on pan-genotypic generic DAA regimens with no pretreatment genotyping was cost-effective compared with scenarios requiring pretreatment HCV genotype tests. Among generic pan-genotypic DAA regimens, SOF/VEL was cost-effective, for people with no cirrhosis and cost-saving for those with cirrhosis.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
hepatitis c virus
climate change
peritoneal dialysis
prognostic factors
dna methylation
single cell
genetic diversity